Jump to Main Content
- Klinngam, Wannita, et al. Show all 8 Authors
- Journal of controlled release 2018 v.292 pp. 183-195
- adverse effects; animal models; bioavailability; cyclophilins; cyclosporine; drug carriers; drug toxicity; eye diseases; half life; humans; hydrophobicity; inhibitory concentration 50; interleukin-2; intravenous injection; macrolides; males; mice; molecular weight; nephrotoxicity; neurotoxicity; pharmacokinetics; polypeptides; protein synthesis; psoriasis; recombinant proteins; rheumatoid arthritis; signal transduction; solubility; subcutaneous injection; temperature; tropoelastin
- ... As a potent macrolide immunosuppressant, cyclosporine A (CsA) is used to treat multiple autoimmune diseases, including non-autoimmune and autoimmune-mediated dry eye disease, rheumatoid arthritis and psoriasis. Despite its potency, CsA has poor solubility, poor bioavailability, and can cause serious adverse reactions such as nephrotoxicity and neurotoxicity. To overcome these limitations, we inven ...